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Abstract 
 
There were approximately 45,000 new cases of pancreatic ductal adenocarcinoma (PDAC) in 
the U.S. in 2013, and approximately 38,500 deaths. PDAC thus constitutes the fourth leading 
cause of cancer deaths in adults, and PDAC patients have a dismal 5-year survival rate of 6%. 
Moreover, approximately 75% of patients die within the first year after diagnosis. PDAC is 
notoriously resistant to chemotherapy and radiation and even with our best treatment options, a 
complete margin-negative surgical resection, few patients achieve long-term survival.  Despite 
these statistics, surprisingly only a small number of NCI-designated cancer centers have a 
specialized pancreatic cancer program. The creation of the IUPUI Signature Center for 
Pancreatic Cancer Research has been the foundation for putting IUPUI, the IU School of 
Medicine, Purdue University and the IU Simon Cancer Center at the forefront of pancreatic 
cancer treatment and research across the nation. The Signature Center, comprised of basic, 
translational and clinical researchers, represents the continuum of the disease from biological / 
molecular investigation to clinical trials. Funding from the Signature Center Initiative is being 
utilized to develop genetically engineered mouse models, generate orthotopic pancreatic cancer 
mouse models, develop cancer associated fibroblast lines to be used as a shared resource as 
well as provide funding for peer reviewed pilot projects led by young investigators.  
Establishment and characterization of these cell lines and in vivo models provides the 
groundwork for these resources to be used by all members in their translational research 
projects. Support of pilot projects provides preliminary data and identification of projects to be 
ultimately used in a SPORE application.  Additionally, work has begun on a web portal to 
promote and educate both patients and clinicians about the IUSCC Pancreas Cancer Clinic 
which became operational in 2010.  Taken together, these activities provide the infrastructure to 
support pancreas cancer research at IU across the continuum of bench to bedside to practice.  
The availability of these resources to all members promotes inter-disciplinary collaborations 
aimed at increasing our understanding of pancreatic cancer so that advancements can be made 
in early diagnosis, prevention and multi-modality targeted treatment of this malignancy.     
 
